EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

KRAS Mutations Are Associated with Shortened Survival in Patients with Epithelioid Malignant Pleural Mesothelioma

Margherita Vannucchi, Veronica Pennati, Clelia Mencaroni, Chiara Defraia, Ledi Bardhi iD, Francesca Castiglione, Cristiana Bellan iD, Camilla Eva Comin

Cancers · 30.03.2023 · 15 (7) · 2072

DOI: 10.3390/cancers15072072 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 30.03.2023. Verfasst von Margherita Vannucchi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Section of Pathology, Department of Medical Biotechnology, University of Siena, 53100 Siena, Italy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Malignant pleural mesothelioma (MPM) is an aggressive malignancy of the pleural surface that includes three major histologic subtypes, epitheliod, sarcomatoid and biphasic. Epithelioid mesothelioma is usually associated with better prognosis. The genetic mechanisms driving MPM, the possible target mutations and the correlation with overall survival remain largely unsettled. We performed target exome sequencing in 29 cases of MPM aimed at identifying somatic mutations and, eventually, their correlation with phenotypic traits and prognostic significance. We found that KRAS mutations, occurring in 13.7% of cases, were associated with shortened median survival (7.6 versus 32.6 months in KRAS wild-type; p = 0.005), as it was the occurrence of any ≥3 mutations (7.6 versus 37.6 months; p = 0.049). Conversely, the presence of KDR single nucleotide polymorphism p.V297I (rs2305948) resulted in a favorable variable for survival (NR versus 23.4 months; p = 0.026). With the intrinsic limitations of a small number of cases and patient heterogeneity, results of this study contribute to the characterization of the mutation profile of MPM and the impact of selected somatic mutations, and possibly KDR polymorphism, on prognosis.

Schlagwörter

Stichwörter der Autor:innen

KDR geneKRAS mutationMPM prognosisepithelioid mesotheliomapleural mesothelioma

Autor:innen und Institutionen

  • Section of Pathology, Department of Medical Biotechnology, University of Siena, 53100 Siena, Italy.
  • Division of Pathological anatomy, Department of Medical and Surgical Critical Care, University of Florence, 50121 Florence, Italy.
  • Department of Experimental and Clinical Medicine, Section of Surgery, Histopathology and Molecular Pathology, University of Florence, 50121 Florence, Italy.

ORCID-Profile: Ledi Bardhi, Cristiana Bellan

Zitieren

APA

Vannucchi, M., Pennati, V., Mencaroni, C., Defraia, C., Bardhi, L., Castiglione, F., Bellan, C., & Comin, C. E. (2023). KRAS Mutations Are Associated with Shortened Survival in Patients with Epithelioid Malignant Pleural Mesothelioma. Cancers, 15(7), 2072. https://doi.org/10.3390/cancers15072072

Vancouver

Vannucchi M, Pennati V, Mencaroni C, Defraia C, Bardhi L, Castiglione F, et al. KRAS Mutations Are Associated with Shortened Survival in Patients with Epithelioid Malignant Pleural Mesothelioma. Cancers. 2023;15(7):2072. doi:10.3390/cancers15072072

BibTeX
@article{Vannucchi2023,
  author = {Vannucchi, Margherita and Pennati, Veronica and Mencaroni, Clelia and Defraia, Chiara and Bardhi, Ledi and Castiglione, Francesca and Bellan, Cristiana and Comin, Camilla Eva},
  title = {KRAS Mutations Are Associated with Shortened Survival in Patients with Epithelioid Malignant Pleural Mesothelioma},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {7},
  pages = {2072},
  doi = {10.3390/cancers15072072}
}
Kostenlos starten →